Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Next Previous
Trial Profile

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Prednisone
  • Indications Polymyalgia rheumatica
  • Focus Therapeutic Use
  • Acronyms SEMAPHORE

    • Most Recent Events

    • 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 03 Jun 2023 Data from this study was used to identify predictive factors of favourable evolution in GC-dependent PMR patients to optimize its management, presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 20 Sep 2022 Primary endpoint has been met. (Low disease activity (PMR-AS10) with steroid independence (GCs 5 mg (absolute value) or decrease 10 mg from week 0 to week 24), as per Results published in the JAMA: the Journal of the American Medical Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top